HUP9903732A2 - cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására - Google Patents

cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására

Info

Publication number
HUP9903732A2
HUP9903732A2 HU9903732A HUP9903732A HUP9903732A2 HU P9903732 A2 HUP9903732 A2 HU P9903732A2 HU 9903732 A HU9903732 A HU 9903732A HU P9903732 A HUP9903732 A HU P9903732A HU P9903732 A2 HUP9903732 A2 HU P9903732A2
Authority
HU
Hungary
Prior art keywords
benign prostatic
prostatic hyperplasia
preparation
pharmaceutical compositions
treating benign
Prior art date
Application number
HU9903732A
Other languages
English (en)
Inventor
Michael Grant Wyllie
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU9903732D0 publication Critical patent/HU9903732D0/hu
Publication of HUP9903732A2 publication Critical patent/HUP9903732A2/hu
Publication of HUP9903732A3 publication Critical patent/HUP9903732A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya eljárás a jóindűlatú prősztatatúltengés, azinstabil hólyag-összehúzódásők és az alsó húgyúti tünetek kezelésére,amely abban áll, hőgy egy ilyen kezelésre szőrűló betegnek valamely, aciklikűs gűanőzin-mőnőfőszfát-szintjét növelő hatóanyagnak, ahatóanyag sójának, szőlvátjának vagy ezek bármelyikét tartalmazógyógyászati készítménynek a hatás kifejtéséhez szükséges mennyiségétadagőlják, adőtt esetben egy a-adrenergantagőnista hatóanyaggalegyütt, mégpedig vagy űgyanabban a gyógyászati készítményben, vagykülön-külön. ŕ
HU9903732A 1998-10-21 1999-10-20 Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia HUP9903732A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10509798P 1998-10-21 1998-10-21

Publications (3)

Publication Number Publication Date
HU9903732D0 HU9903732D0 (en) 1999-12-28
HUP9903732A2 true HUP9903732A2 (hu) 2000-08-28
HUP9903732A3 HUP9903732A3 (en) 2002-01-28

Family

ID=22304008

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903732A HUP9903732A3 (en) 1998-10-21 1999-10-20 Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia

Country Status (11)

Country Link
EP (1) EP1020190A3 (hu)
JP (1) JP2000128804A (hu)
KR (1) KR20000029222A (hu)
AR (1) AR020850A1 (hu)
AU (1) AU5597799A (hu)
CA (1) CA2287122A1 (hu)
CO (1) CO5150210A1 (hu)
HU (1) HUP9903732A3 (hu)
IL (1) IL132406A0 (hu)
PE (1) PE20001282A1 (hu)
ZA (1) ZA996622B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
BRPI0014526C1 (pt) 1999-09-16 2021-05-25 Mitsubishi Tanabe Pharma Corp compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
WO2002062389A1 (fr) * 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
NZ527741A (en) 2001-02-26 2005-02-25 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
AR058119A1 (es) * 2005-12-20 2008-01-23 Pfizer Prod Inc Combinacion farmaceutica para el tratamiento de sintomas del tracto urinario inferior (stui)
RU2010115647A (ru) * 2007-10-02 2011-11-10 Донг-А Фарм.Ко., Лтд. (Kr) Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей
KR20110062943A (ko) * 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
EP2875824B1 (en) 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Composition for preventing or treating cachexia
WO2013167299A1 (en) 2012-05-11 2013-11-14 Kael-Gemvax Co., Ltd. Anti-inflammatory peptides and composition comprising the same
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US9907838B2 (en) 2013-04-19 2018-03-06 Gemvax & Kael Co., Ltd. Composition and methods for treating ischemic damage
RU2677277C2 (ru) 2013-06-07 2019-01-16 Джемвакс Энд Каэл Ко., Лтд. Биологические маркеры, которые могут быть использованы в иммунотерапии рака
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
ES2773296T3 (es) 2013-10-23 2020-07-10 Gemvax & Kael Co Ltd Composición para tratar y prevenir la hiperplasia prostática benigna
US10034922B2 (en) 2013-11-22 2018-07-31 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
WO2015156649A1 (ko) 2014-04-11 2015-10-15 주식회사 젬백스앤카엘 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US10662223B2 (en) 2014-04-30 2020-05-26 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
KR102638286B1 (ko) 2015-07-02 2024-02-20 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
DE19642322A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Neue 3-Heterocyclyl-substituierte Pyrazolderivate
DE19709126A1 (de) * 1997-03-06 1998-09-10 Bayer Ag Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine
AU3621097A (en) * 1997-07-09 1999-02-08 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases

Also Published As

Publication number Publication date
AU5597799A (en) 2000-05-04
HUP9903732A3 (en) 2002-01-28
JP2000128804A (ja) 2000-05-09
EP1020190A3 (en) 2000-10-25
EP1020190A2 (en) 2000-07-19
AR020850A1 (es) 2002-05-29
CO5150210A1 (es) 2002-04-29
CA2287122A1 (en) 2000-04-21
IL132406A0 (en) 2001-03-19
HU9903732D0 (en) 1999-12-28
ZA996622B (en) 2001-04-20
KR20000029222A (ko) 2000-05-25
PE20001282A1 (es) 2000-11-18

Similar Documents

Publication Publication Date Title
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
RS20110564A2 (en) ONE-DAY OXYCODON FORMULATIONS
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
HUP9802339A2 (hu) Darifenacint tartalmazó gyógyászati készítmények
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
KR880002515A (ko) 흡수 및 작용이 빠른 설린다크 또는 나트륨 설린다크와 염기의 혼합물
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
MA28072A1 (fr) Ecorces de levures pour le traitement ou la prevention de l'hyperglycemie ou pour la stabilisation de la glycemie
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
KR880007073A (ko) 의 약 품
JP2004537500A5 (hu)
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
HUP0203303A2 (hu) Készítmény taxánok humán betegeknek történő orális adagolására
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
Becher Topical alprostadil cream for the treatment of erectile dysfunction
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente